Head and Neck

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(CCTG) HN.9/LA-OSCCRandomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC)Meyers, Dr BrandonOpen to recruitmentNCT03410615
(GSK) 209227 / INDUCE-4A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination with Pembrolizumab and 5FU-Platinum Chemotherapy versus Placebo in Combination with Pembrolizumab plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaMeyers, Dr BrandonOpen to recruitmentNCT04428333
(JCC) SHINE / HNSBRTA Phase 2 Study of SBRT for Squamous Cell Carcinoma of the Head and NeckLee, Dr JustinOpen to recruitmentNCT04435938
(LHRI) RADIO/Cisplatin Hearing Loss/Cisplatin HD vs LDRandomized Assessment of Cisplatin Dosing Interval for Ototoxicity in the treatment of locally advanced head and neck squamous cell carcinoma (LAHNSCC) undergoing curative concurrent chemoradiotherapy (RADIO)Meyers, Dr BrandonOpen to recruitmentNCT03649048
(GSK) 209229 / INDUCE-3A Randomized, Open-label, Adaptive, Phase II/III Study of Pembrolizumab with or without GSK3359609 for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaMeyers, Dr BrandonSuspended/On holdNCT04128696
Download PDF